不同干粉剂吸入治疗对支气管哮喘患者炎性因子的影响及其临床价值

Effect of Different Kinds of Powder Inhalation Therapy on Inflammatory Factors of the Patients with Bronchial Asthma and Its Clinical Value

目的探讨布地奈德/福莫特罗与沙美特罗/丙酸氟替卡松对支气管哮喘患者炎性因子水平及呼吸功能的影响。方法将2011年1月至2012年12月中国长城铝业公司职工总医院收治的180例支气管哮喘患者纳入研究,分为布地奈德/福莫特罗组(A组)和沙美特罗/丙酸氟替卡松组(B组),检测治疗后两组患者炎性因子的水平及呼吸功能指标,并分析两者的相关性。结果治疗后,两组患者白细胞介素(IL)-5、IL-17、IL-33的水平均显著低于治疗前,且A组患者IL-5、IL-17、IL-33的水平显著低于B组(P<0.05);治疗后,两组患者最大呼气流速(PEF)、第一秒用力呼气容积/用力肺活量(FEV1/FVC)均显著高于治疗前,且A组显著高于B组(P<0.05)。IL-5、IL-17、IL-33的水平与PEF、FEV1/FVC呈负相关。结论布地奈德/福莫特罗治疗支气管哮喘的疗效较沙美特罗/丙酸氟替卡松更好,能有效地控制呼吸道局部的炎性反应、改善呼吸功能。

Objective To study the effect of budesonide/formoterol and salmeterol/flutieasone propio- nate on inflammatory factors and respiratory function of the patients with bronchial asthma. Methods Total of 180 patients with bronchial asthma in Changcheng Aluminum Company Affiliated Hospital from Jan. 2011 to Dec. 2012 were enrolled and divided into budesonide/formoterol group and salmeterol/fluticasone propiohate group by random number table method. Then,lnflammatory factor level,respiratory function index were detected and the correlation were analyzed. Results After treatment, the level of IL-5, IL-17, IL-33 of the two group were lower than before treatment and IL-5 ,IL-17 ,IL-33 levels of budesonide/formoterol group were signficantly lower than salmeterol/fluticasone propionate group （P 〈 0.05 ）. PEF, FEV1/FVC% of the two group were higher than before treatment and PEF, FEV1/FVC% of budesonide/formoterol group were significandy higher than salmeterol/fluticasone group propionate （ P 〈 0.05 ）. PEF, FEV1/FVC were negatively correlated with IL-5, IL-17, IL-33 levels. Conclusion Clinical effect of budesonide/formoterol on treating bronchial asthma is better than salmeterol/fluticasone propionate and it can effectively control airway inflammation and impmve respiratory function.